{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:05:17Z","timestamp":1776413117306,"version":"3.51.2"},"posted":{"date-parts":[[2025,11,15]]},"group-title":"Gastroenterology","reference-count":24,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Obesity is a risk factor for relapsing inflammatory bowel disease. GLP-1 and dual GLP-1\/GIP agonists may offer superior weight loss; however, their effect on inflammatory bowel disease remains unknown. In this study, we assessed outcomes in patients with IBD and obesity using these medications.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective, propensity-matched analysis was conducted using data from The OneFlorida+ network. We evaluated patients with IBD and obesity prescribed GLP-1-based therapy (liraglutide, semaglutide, or tirzepatide) versus those without. 562 patients prescribed GLP-1-based therapies were matched 1:1 to controls based on demographics and comorbidities.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>No differences in GLP-1 users versus non-users with respect to all-cause hospitalization, IBD-hospitalization, IBD-related surgery, or pancreatitis were seen. Use of semaglutide reduced the risk of IBD-related surgery (HR 0.33, CI 0.13-0.83). Among 89 tirzepatide users, none required IBD-related surgery versus 2 matched controls. Black GLP-1 users had an increased risk of all-cause hospitalizations (HR 1.59, CI 1.11\u20132.29) but not IBD-related hospitalization or IBD-related surgery. Steroid use was comparable between groups. GLP-1 use significantly reduced serum CRP.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Semaglutide appeared to lower the risk of IBD-related surgery. Black patients using GLP-1 therapy had an increased risk of all-cause hospitalization. Tirzepatide showed no significant difference regarding primary endpoints; however, the sample size was small. Overall, all GLP-1-based therapies were well tolerated among obese patients with IBD. Larger studies are warranted to understand the therapeutic potential of GLP-1-based treatment in this patient population.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Graphical Abstract<\/jats:title>\n                  <jats:fig id=\"ufig1\" position=\"float\" orientation=\"portrait\" fig-type=\"figure\">\n                    <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"25340005v1_ufig1\" position=\"float\" orientation=\"portrait\"\/>\n                  <\/jats:fig>\n                <\/jats:sec>","DOI":"10.1101\/2025.11.13.25340005","type":"posted-content","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T23:20:14Z","timestamp":1763248814000},"source":"Crossref","is-referenced-by-count":0,"title":["Effect of Injectable Dual and Single Agonist Glucagon-Like Peptide-1 Based Therapy on Inflammatory Bowel Disease Activity Among Patients with Obesity"],"prefix":"10.64898","author":[{"given":"Jake","family":"Levine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3971-4242","authenticated-orcid":false,"given":"Yao An","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9799-2592","authenticated-orcid":false,"given":"Jingchuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7950-3759","authenticated-orcid":false,"given":"Hao","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0061-0637","authenticated-orcid":false,"given":"Rotana M","family":"Radwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2238-5429","authenticated-orcid":false,"given":"Jiang","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7802-7890","authenticated-orcid":false,"given":"Aleksey","family":"Novikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9589-7727","authenticated-orcid":false,"given":"Amy","family":"Sheer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025111802401647000_2025.11.13.25340005v1.1","doi-asserted-by":"publisher","DOI":"10.3389\/phrs.2021.1603990"},{"key":"2025111802401647000_2025.11.13.25340005v1.2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i22.2723"},{"key":"2025111802401647000_2025.11.13.25340005v1.3","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000608"},{"key":"2025111802401647000_2025.11.13.25340005v1.4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328174"},{"key":"2025111802401647000_2025.11.13.25340005v1.5","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11123256"},{"key":"2025111802401647000_2025.11.13.25340005v1.6","doi-asserted-by":"crossref","unstructured":"Yarur, Andres J. et al. Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study. Gastroenterology, Volume 165, Issue 4, 963\u2013975.e5","DOI":"10.1053\/j.gastro.2023.06.036"},{"key":"2025111802401647000_2025.11.13.25340005v1.7","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231222367"},{"key":"2025111802401647000_2025.11.13.25340005v1.8","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz236"},{"key":"2025111802401647000_2025.11.13.25340005v1.9","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0001035224.59649.53"},{"key":"2025111802401647000_2025.11.13.25340005v1.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410819"},{"key":"2025111802401647000_2025.11.13.25340005v1.11","unstructured":"PCORnet\u00ae Common Data Model. The National Patient-Centered Clinical Research Network. Accessed April 9, 2025. https:\/\/pcornet.org\/data\/common-data-model\/"},{"key":"2025111802401647000_2025.11.13.25340005v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2017.08.010"},{"key":"2025111802401647000_2025.11.13.25340005v1.13","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2020.01.33"},{"key":"2025111802401647000_2025.11.13.25340005v1.14","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezy167"},{"key":"2025111802401647000_2025.11.13.25340005v1.15","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"2025111802401647000_2025.11.13.25340005v1.16","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13185"},{"key":"2025111802401647000_2025.11.13.25340005v1.17","doi-asserted-by":"crossref","unstructured":"The Complex Contributors to Obesity-Related Health Disparities: Introduction to the Special Issue. Fouad, Mona N . et al. American Journal of Preventive Medicine, Volume 63, Issue 1, S1\u2013S5","DOI":"10.1016\/j.amepre.2022.03.022"},{"key":"2025111802401647000_2025.11.13.25340005v1.18","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-023-00506-3"},{"key":"2025111802401647000_2025.11.13.25340005v1.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394"},{"key":"2025111802401647000_2025.11.13.25340005v1.20","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-024-03571-7"},{"key":"2025111802401647000_2025.11.13.25340005v1.21","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000001650"},{"key":"2025111802401647000_2025.11.13.25340005v1.22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14030944"},{"key":"2025111802401647000_2025.11.13.25340005v1.23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1214334"},{"key":"2025111802401647000_2025.11.13.25340005v1.24","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003525"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.11.13.25340005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:51:11Z","timestamp":1768510271000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.11.13.25340005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":24,"URL":"https:\/\/doi.org\/10.1101\/2025.11.13.25340005","relation":{},"subject":[],"published":{"date-parts":[[2025,11,15]]},"subtype":"preprint"}}